October 29, 2015 5:39pm

 

Here we are again, the prior day's rally set an expectation of profit taking. Like the red coats, Q3 financial results/earning’s releases are coming which will identify the “powder” left for Q4 and year’s end.

Subscription required, read more … http://www.regmedinvestors.com/user/register

 

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

U.S. stocks traded in a range Thursday, following the prior day's rally, as investors weighed the possibility of a December rate hike and eyed earnings

The NASDAQ closed DOWN -21.42 or -0.42% to 5,074.27 and the DOW closed DOWN -13.42 or -0.08% to 17,766.10.

 

 

Henry’omics:

  • As I had said, I am always thankful to start the day - UP day but, we usually pay the price for the past day or in the day ahead – the shell game continues!
  • The stem, cell, gene therapy and regenerative medicine (SCGT&RM) opened to the upside and stayed positive through the mid-day and then the usual calamity – profit taking.

Volume stays low with no reason but, little resonance!

  • The 3 pm Advance/decline lie (A/DL) set the expectation of a short-term orientation to the sector as the closing bell was calibrated to the downside!

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed Thursday closed down -3.24 or -0.98% following Wednesday’s +4.14 or +1.26% after Tuesday’s advance of +10.20 or +3.215 following Monday’s +1.17 or +0.37%;
  • The NASDAQ Biotechnology index (NBI) closed Thursday down -26.88 or -0.77% following Wednesday’s  advance of +45.69 or +1.33% after Tuesday’s advance of +99.44 or +2.99% following Monday’s advance of +27.14 or +0.82%;
  • The Russell 2000 (IWM) closed Thursday down -1.25 or -1.07% following Wednesday’s advance of  +3.32 or +2.92% after Tuesday’s decline of -1.26 or -1.10% following Monday’s decline of -0.79 or -0.68%;
  • The SPDR SD&P Biotech ETF (XBI) closed Thursday down -1.78 or -2.58% following Wednesday ‘s advance of +1.73 or +2.57% after Tuesday’s advance of +1.44 or +2.19% following Monday’s advance of +0.20 or +0.30%;

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • The SCGT & RM equities opened positive with an A/DL of 29/11 and 3 flats staying positive but slipping to the mid-day A/DL of 22/19 and 2 flats;
  • The 3 pm A/DL roiled the sector dropping the A/DL negative to 12/29 and 2 flats with the closing bell synched negative to the day to end the session with an A/DL of 14/27 and 2 flats.

My fear index, the CBOE Volatility Index (VIX) traded Thursday below 14 after Wednesday near 14 following Tuesday’s above 15 after Monday’s near 15.

 

 

Dosing the sector – what a day for the 43 Patients:

  • Open: POSITIVE with 29 decliners, 11 advances and 3 flats;
  • Mid-day (1 pm): POSITIVE with 19 decliners, 22 advancers and 2 flats;
  • 3 pm: NEGATIVE with 29 decliners, 12 advancers and 2 flats;
  • Closing bell: NEGATIVE with x decliners, y advancers and 3 flats

 

 

Thursday’s trading indications:  4 hits/ 6 miss

  • Capricor (CAPR) closed UP – miss;
  • Fate Therapeutics (FATE) closed UP – hit;
  • Intrexon (XON) closed DOWN – hit;
  • Histogenics (HSGX) closed DOWN – hit;
  • Juno Therapeutics (JUNO) closed DOWN – miss;
  • Ocata Therapeutics (OCATA) closed UP – miss;
  • MiMedx (MDXG) closed DOWN – miss;
  • Northwest Bio (NWBO) closed DOWN – hit;
  • Sangamo (SGMO) closed UP – miss;
  • Verastem (VSTM closed DOWN – miss;

 

 

Who is down – top 5:

  • Bluebird bio (BLUE) closed down -$6.63 to $79.09;
  • Kite Pharma (KITE) -$2.67 to $68.77;
  • Spark Therapeutics ONCE) -$2.44 to $55.11;
  • MiMedx (MDXG) -$2.20 to $7.29;
  • Juno Therapeutics (JUNO) closed down -$2.17 to $51.39;

 

 

Who was UP – top 5:

  • Cellectis ADR (CLS) closed up +$1.15 to $26.09;
  • Sangamo (SGMO) +$0.55 to $7.69;
  • Regenxbio (RGNX) +$0.33 to $15.54;
  • Fate Therapeutics (FATE) +$0.15 to $4.46;
  • ReNeuron (RENE.L) closed up +40.13 to $3.75

 

 

Flat:

  • StemCells (STEM) at $0.39;
  • VistaGen (VSTA) at $7.49

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.